Superworth

Rein Therapeutics EPS RNTX

Diluted earnings per share by quarter and over the last twelve months, from 2016.

Last 12 months, to Jun 30, 2026
−$1.59
Latest quarter, Q2 FY26
−$0.10
Fiscal year 2025
−$1.83

Rein Therapeutics' earnings per share was −$1.59 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.10.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.83n/a
FY2024−$3.47n/a
FY2023−$3.38n/a
FY2022−$6.02n/a
FY2021−$5.80n/a
FY2020−$12.60n/a
FY2019−$25.80n/a
FY2018−$42.80n/a
FY2017−$449.60n/a
FY2016−$847.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.10n/a−$1.59
Q1 FY26−$0.19n/a−$1.77
Q4 FY25−$1.09n/a−$1.83
Q3 FY25−$0.21n/a−$2.63
Q2 FY25−$0.28n/a−$2.69
Q1 FY25−$0.25n/a−$2.86
Q4 FY24−$1.89n/a−$3.47
Q3 FY24−$0.27n/a−$3.12
Q2 FY24−$0.45n/a−$3.25
Q1 FY24−$0.86n/a−$3.19
Q4 FY23−$1.54n/a−$3.38
Q3 FY23−$0.40n/a−$2.84

Against its peers

Companies in Drug Manufacturers - General nearest Rein Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RNTXRein Therapeutics−$1.59
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Rein Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.